Journal of Biological Chemistry · 2003 · 77 citations · 31 references
Life SciencesBiochemistryMolecular BiologyGene ExpressionMolecular VirologyVirologyProtein OligomerizationViral Gene ExpressionViral InfectionsViral ReplicationViral StructureViral TranscriptionOligomerization MechanismsTranscriptional Regulation In VirusesViral Nucleocapsid StructureViral Protein OligomerizationViral Rna SynthesisViral Rna TranslationViral Transcription FactorsViral Transcription Mechanisms
Transcription of Ebola virus (EBOV)-specific mRNA is driven by the nucleocapsid proteins NP, VP35, and L. This process is further dependent on VP30, an essential EBOV-specific transcription factor. The present study addresses the self-assembly of VP30 and the functional significance of this process for viral transcription and propagation. Essential for oligomerization of VP30 is a region spanning amino acids 94–112. Within this region a cluster of four leucine residues is of critical importance. Mutation of only one of these leucine residues resulted in oligomerization-deficient VP30 molecules that were no longer able to support EBOV-specific transcription. The essential role of homo-oligomerization for the function of VP30 was further corroborated by the finding that mixed VP30 oligomers consisting of VP30 and transcriptionally inactive VP30 mutants were impaired in their ability to support EBOV transcription. The dominant negative effect of these VP30 mutants was dependent on their ability to bind to VP30. The oligomerization of VP30 could be dose dependently inhibited by a 25-mer peptide (E30pep-wt) derived from the presumed oligomerization domain (IC50,1 μm). A control peptide (E30pep-3LA), in which three leucines were changed to alanine, had no inhibitory effect. Thus, E30pep-wt seemed to bind efficiently to VP30 and consequently blocked the oligomerization of the protein. When E30pep-wt was transfected into EBOV-infected cells, the peptide inhibited viral replication suggesting that inhibition of VP30 oligomerization represents a target for EBOV antiviral drugs. Transcription of Ebola virus (EBOV)-specific mRNA is driven by the nucleocapsid proteins NP, VP35, and L. This process is further dependent on VP30, an essential EBOV-specific transcription factor. The present study addresses the self-assembly of VP30 and the functional significance of this process for viral transcription and propagation. Essential for oligomerization of VP30 is a region spanning amino acids 94–112. Within this region a cluster of four leucine residues is of critical importance. Mutation of only one of these leucine residues resulted in oligomerization-deficient VP30 molecules that were no longer able to support EBOV-specific transcription. The essential role of homo-oligomerization for the function of VP30 was further corroborated by the finding that mixed VP30 oligomers consisting of VP30 and transcriptionally inactive VP30 mutants were impaired in their ability to support EBOV transcription. The dominant negative effect of these VP30 mutants was dependent on their ability to bind to VP30. The oligomerization of VP30 could be dose dependently inhibited by a 25-mer peptide (E30pep-wt) derived from the presumed oligomerization domain (IC50,1 μm). A control peptide (E30pep-3LA), in which three leucines were changed to alanine, had no inhibitory effect. Thus, E30pep-wt seemed to bind efficiently to VP30 and consequently blocked the oligomerization of the protein. When E30pep-wt was transfected into EBOV-infected cells, the peptide inhibited viral replication suggesting that inhibition of VP30 oligomerization represents a target for EBOV antiviral drugs. Ebola virus (EBOV), 1The abbreviations used are: EBOV, Ebola virus; CAT, chloramphenicol acetyltransferase; wt, wild type.1The abbreviations used are: EBOV, Ebola virus; CAT, chloramphenicol acetyltransferase; wt, wild type. a filovirus, causes sporadic outbreaks of a fatal hemorrhagic fever in Africa (1World Health OrganizationWkly. Epidemiol. Rec. 2001; 76: 41-48PubMed Google Scholar, 2World Health OrganizationEpidemiol. Bull. 1995; 16: 16PubMed Google Scholar, 3Bowen E.T. Lloyd G. Harris W.J. Platt G.S. Baskerville A. Vella E.E. Lancet. 1977; 1: 571-573Abstract PubMed Scopus (166) Google Scholar, 4World Health OrganizationWkly. Epidemiol. Rec. 1999; 74: 145PubMed Google Scholar). Since the natural host of the virus is not yet identified, the outbreaks are unpredictable and so are the risk factors for the population in the endemic areas in central Africa. To date, neither a vaccine nor a treatment of the EBOV infection are available. The enveloped EBOV particles are composed of seven structural proteins and the negative sense RNA genome. Four viral proteins NP, VP35, L, and VP30 are the constituents of the nucleocapsid. The main component of the nucleocapsid complex is NP, a heavily phosphorylated protein, that encapsidates the genomic RNA and forms intracellular inclusions upon recombinant expression (5Sanchez A. Kiley M.P. Holloway B.P. McCormick J.B. Auperin D.D. Virology. 1989; 170: 81-91Crossref PubMed Scopus (50) Google Scholar, 6Elliott L.H. Kiley M.P. McCormick J.B. Virology. 1985; 147: 169-176Crossref PubMed Scopus (165) Google Scholar). The NP inclusions are morphologically highly similar to the inclusions formed during EBOV infection of target cells. VP35 and L are the components of the viral polymerase. VP30 represents an EBOV-specific transcription activation factor (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar). Most viruses of the order Mononegavirales contain three proteins, N (NP), P, and L, that drive the processes of replication (synthesis of genomic RNA) and transcription (synthesis of viral mRNAs). These proteins also constitute the respective viral nucleocapsid complex. N (or NP) represents the major nucleocapsid protein that encapsidates the viral genome. The encapsidated genome serves as a template for the viral polymerase complex, which is constituted by the catalytic subunit L and the cofactor P (8Conzelmann K.K. Annu. Rev. Genet. 1998; 32: 123-162Crossref PubMed Scopus (165) Google Scholar). An EBOV-specific minigenome-based reverse genetic system revealed that EBOV follows another strategy to synthesize the different RNA species. NP, VP35 (the P analogue), and L were sufficient for viral replication, similar to the other Mononegavirales. The fourth nucleocapsid protein, VP30, although not influencing replication, dramatically activated the synthesis of the viral mRNAs (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar, 9Volchkov V.E. Volchkova V.A. Mühlberger E. Kolesnikova L.V. Weik M. Dolnik O. Klenk H.D. Science. 2001; 291: 1965-1969Crossref PubMed Scopus (249) Google Scholar). The exact mechanism of how VP30 activates transcription is still unclear. Recent investigations have suggested that VP30 most probably is effective at a very early stage of transcription. Transcription of the EBOV minigenomes could take place in the absence of VP30 if an RNA secondary structure that includes the transcription start site of the first gene (NP) is destroyed (10Weik M. Modrof J. Klenk H.D. Becker S. Mühlberger E. J. Virol. 2002; 76: 8532-8539Crossref PubMed Scopus (120) Google Scholar). Thus, one function of VP30 during transcription might be to overcome this barrier. Transcription activation by VP30 is strongly regulated by the phosphorylation state of VP30. While the non- or weakly phosphorylated protein activates transcription, the fully phosphorylated VP30 is strongly inhibited in this function. In contrast, the binding of VP30 to nucleocapsid-like structures that are formed by the major nucleocapsid protein NP is inversely regulated. The phosphorylated VP30 binds to the nucleocapsid-like structures, whereas the nonphosphorylated protein does not (11Modrof J. Mühlberger E. Klenk H.D. Becker S. J. Biol. Chem. 2002; 277: 33099-33104Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar). VP30 contains a nonconventional zinc finger whose integrity is a prerequisite for the function of the protein (12Modrof J. Becker S. Mühlberger E. J. Virol. 2003; 77: 3334-3338Crossref PubMed Scopus (69) Google Scholar). In the present study we have investigated whether VP30, like many other transcription factors, is a homo-oligomer and, if so, whether the oligomerization is essential for its function. It was found that VP30 is, indeed, present as an oligomer. Relevant for oligomerization is a stretch of ∼20 amino acids flanking a central tetraleucine cluster whose integrity is essential for VP30 self-association. While oligomerization is not needed for the interaction of VP30 with the EBOV nucleocapsid, oligomerization of VP30 is essential for the transactivating function and for the propagation of EBOV in cell culture. Viruses and Cell Lines—EBOV-Zaire strain Mayinga was grown and passaged under biosafety level 4 conditions as described elsewhere (13Becker S. Feldmann H. Will C. Slenczka W. Med. Microbiol. Immunol. 1992; 181: 43-55Crossref PubMed Scopus (53) Google Scholar). The recombinant vaccinia virus MVA-T7 was grown and titered in chicken embryo fibroblasts (14Sutter G. Ohlmann M. Erfle V. FEBS Lett. 1995; 371: 9-12Crossref PubMed Scopus (201) Google Scholar). Monolayer cultures of HeLa cells were used for all experiments with the recombinant vaccinia virus MVA-T7, and cells were cultured as described by Mühlberger et al. (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar). BSR T7/5 cells (a BHK-21 cell clone), which constitutively expressed T7 RNA polymerase, were cultured as described by Buchholz et al. (15Buchholz U.J. Finke S. Conzelmann K.K. J. Virol. 1999; 73: 251-259Crossref PubMed Google Scholar). For transfection experiments, cells were grown in 6-well plates (7 cm2). HUH7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Molecular Cloning of VP30 and VP30 Mutants—For expression of VP30 and the VP30 mutants, the respective genes were cloned into the plasmid pTM1 under the control of the T7 RNA polymerase promoter (16Fuerst T.R. Niles E.G. Studier F.W. Moss B. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 8122-8126Crossref PubMed Scopus (1861) Google Scholar). The cloning of pT-VP30f, pT-VP30, and pT-VP30ΔN2–68 has been described previously (11Modrof J. Mühlberger E. Klenk H.D. Becker S. J. Biol. Chem. 2002; 277: 33099-33104Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar). Cloning of the Mutants pT-VP30fΔC114–288 and pT-VP30ΔC114–288— The coding region for amino acids 1–113 of the VP30 gene was amplified by PCR using pT-VP30 as template. For synthesis of pT-VP30fΔC the primers 410 (5′-ACC GGA TCC ATG GAC TAC AAG GAC GAC GAT GAC AAG GAA GCT TCA TAT GAG AGA GGA CG-3′) and 711 (5′-AGA CTC GAG TTA TTC TAC TGA TCC ACA AGT CTT ACG G-3′) were used. 410, the forward primer, contained a BamHI restriction site (underlined) and the sequence encoding the FLAG epitope (abbreviated f). The reverse primer 711 contained an XhoI restriction site (underlined). To construct pT-VP30ΔC, the forward primer 408 (5′-ACC GGA TCC ATG GAA GCT TCA TAT GAG AGA-3′) was used in combination with 711. The resulting DNA fragments were cloned into the plasmid pTM1. Cloning of the Mutants pT-VP30Δ 72–112 and pT-VP30fΔ 72–93—For the internal deletions of the mutants pT-VP30fΔ72–112 and pT-VP30Δ72–93 a second PshAI restriction site was inserted into the vector pT-VP30f at position 8721 (EBOV genome) in the case of pT-VP30fΔ72–112 or at position 8786 for the construct pT-VP30Δ72–93 using the QuikChange site-directed mutagenesis kit (Stratagene). The resulting vector was digested with PshAI, the DNA fragments encoding either amino acids 72–112 or 72–93 were removed, and the remaining fragments were religated. Cloning of VP30 Substitution Mutants—Cloning of the VP30 substitution mutants was performed using the QuikChange site-directed mutagenesis kit (Stratagene) with either pT-VP30f, pT-VP30, pT-VP30fΔN, or pT-VP30fΔC as template. All mutants were verified by sequencing. Ebola Virus Transcription Analysis—BSR T7/5 cells (5 × 105 in a 7-cm2 well) were transfected with plasmids encoding the EBOV nucleocapsid proteins NP, VP35, VP30 (or/and VP30 mutants), L, and an EBOV-specific minigenome containing the CAT reporter gene (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar) using FuGENE 6 (Roche Applied Science) according to the supplier's protocol. Cells were incubated at 37 °C for 8–12 and with Dulbecco's modified Eagle's medium and further incubated in Dulbecco's modified Eagle's medium containing 10% fetal calf for at 37 cells were and CAT as a for transcription was CAT was using a Biol. PubMed Scopus Google Scholar). of the was with a by using the were by M. at the of Molecular and of The E30pep-wt and were derived from the Ebola virus VP30 amino sequence in the leucines at position were by In with and pT-VP30f were in and with using the T7 system according to the supplier's protocol. the in were in different are in of in was into of with the was performed as described elsewhere J. C. Kolesnikova L. B. A. Mühlberger E. Becker S. Virology. 2001; PubMed Scopus Google Scholar). and transfection of HeLa cells, with and were as described by Modrof et al. J. C. Kolesnikova L. B. A. Mühlberger E. Becker S. Virology. 2001; PubMed Scopus Google Scholar). VP30 oligomerization of VP30, we of the that the of a FLAG epitope to the of VP30 resulted in a of the protein that is from VP30 expression of and VP30 and the that was used the protein not VP30 and upon the proteins that VP30 with and the mixed oligomers were An interaction and VP30 was only proteins were of VP30 and not to of not These that VP30 or synthesis and the formed oligomers are and not J. A. Virology. 1995; PubMed Scopus Google Scholar). of the the oligomerization site of VP30, and mutants as as internal mutants of VP30 were and used in a VP30 and VP30 mutants were expressed in HeLa cells, and cell were to with an Mutants the and the amino acids were still able to with VP30 and While an internal of amino acids 72–93 VP30 in an state of amino acids 72–112 oligomerization Thus, amino acids are essential for oligomerization of VP30. a of the amino sequence of the region B. C. J. Biol. PubMed Scopus Google Scholar) an structure amino residues Within this a cluster of four leucines was most To the significance of this cluster for the oligomerization of VP30, leucine residues were by was also as a of and VP30 mutants were in HeLa cells, and with an in the tetraleucine impaired oligomerization of VP30 if only one of the leucine residues was changed to of the cell with an the of the VP30 mutants not the VP30 and the was whether the oligomerization of VP30 is essential for the ability of the protein to with the nucleocapsid of To this we of the that upon with the major nucleocapsid protein NP the VP30 into inclusions and J. Mühlberger E. Klenk H.D. Becker S. J. Biol. Chem. 2002; 277: 33099-33104Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar). When the oligomerization-deficient was with NP, proteins were still in the inclusions suggesting that the oligomerization of VP30 is not essential for its binding to NP inclusions Essential for Transcription by VP30 was of whether the oligomerization of VP30 EBOV-specific transcription. This was investigated by using an EBOV-specific transcription system that is only in the of VP30 (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar). VP30 activates the transcription of an EBOV-specific minigenome that contains a CAT reporter The resulting CAT is a for the EBOV-specific transcription and and E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar). In this the VP30 was by the VP30 substitution mutants and the effect of the was by the CAT reporter gene of the substitution mutants was able to EBOV transcription strongly suggesting that oligomerization of VP30 is for EBOV transcription. To this we investigated the oligomerization of functional VP30 molecules is essential for transcription mixed oligomers of VP30 and inactive VP30 mutants that still contain an oligomerization domain or be impaired in their ability to transcription. In contrast, a combination of VP30 and inactive VP30 mutants, which not bind to VP30 the presumed oligomerization site contained leucine to and the transcription activation function of VP30 of VP30 mutants was with the that and to be inactive and a transcription was VP30 and either or CAT reporter gene was at The transcription that was using VP30 was to A and The of or to a of transcription and In contrast, the of or that are inactive bind to VP30 not the of the transcription system and The protein expression of VP30 and the VP30 mutants had been by A and the have been in with the described the mutants that had changed only one leucine to and to be dominant negative like and and we presumed that the mutants containing only a leucine substitution were still able to bind to VP30 and the negative effect. To this mutants were with or and with an The revealed indeed, was able to with VP30, although binding was The no interaction with VP30 no was if the VP30 protein and the contained a of one leucine to The the of the oligomerization of VP30 with an inactive VP30 inhibited the transactivating function of VP30. Thus, be that the oligomerization of VP30 is the prerequisite for the function of VP30 as a and inactive mutants of VP30 that are able to a dominant negative of VP30 further the oligomerization of VP30, we used that were derived from the presumed oligomerization domain to whether these could the self-assembly of VP30. of the used was to amino acids the other contained three leucine to VP30 and VP30 were in in the of of the E30pep-wt or μm). the VP30 was with an the was by and the of and VP30 was and The of E30pep-wt during the of VP30 and resulted in a inhibition of the oligomerization of VP30 and The for the inhibition was The of of the control peptide had no effect on oligomerization and The not the expression of VP30 or To these consisting of the amino acids of VP30 were sufficient to with VP30 for its binding to Essential for the ability of the peptide to bind VP30 was the of a leucine cluster at Thus, these amino acids seemed to be sufficient to bind and the oligomerization site of VP30. support the that VP30 oligomerization is essential for the of the protein in viral transcription and that the oligomerization is by amino acids a tetraleucine cluster whose is of VP30 on EBOV we whether VP30 oligomerization was also essential for the propagation of EBOV in cell culture. Thus, cells were transfected with the peptide E30pep-wt or and with the of cells was by the of the NP found that the of not inhibited the EBOV infection that oligomerization of VP30 an essential role for the replication of EBOV with EBOV-infected HUH7 cells the not of the coding of the EBOV genome the virus the genomic to the that EBOV proteins have This has been for the protein that on the one of viruses and on the other is an factor for viral M. J. J. Virol. 2003; 77: PubMed Scopus Google Scholar, J. G. S. S. W. J. Biol. 2003; PubMed Scopus Google Scholar, H. E. A. H. J. Virol. 2002; 76: PubMed Scopus Google Scholar). is VP35, the cofactor of the viral polymerase L. VP35 is essential for viral RNA synthesis and the of the host cell (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar, Mühlberger E. Volchkov V. J. Klenk H.D. A. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar). It is whether and how the different of the proteins are regulated. is on the of the of VP30. It has been that the protein is not only an of viral transcription is also in the of the viral nucleocapsid. The the of VP30 is presumed to be by phosphorylation of residues in the N of the (11Modrof J. Mühlberger E. Klenk H.D. Becker S. J. Biol. Chem. 2002; 277: 33099-33104Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar). In the present we on the function of another or of VP30, the homo-oligomerization of the protein. investigated whether the homo-oligomerization of VP30 is for binding to the nucleocapsid, the transcription or To this we first the homo-oligomerization domain of EBOV VP30 and found that amino acids are essential for critical was a cluster of four leucine residues the the of one of the leucines was sufficient to the self-assembly of VP30 In on the of and B. C. J. Biol. PubMed Scopus Google Scholar) an structure that amino residues It is presumed that oligomerization of VP30 is dependent on the of the The of the complex has yet to be of viral proteins whose oligomerization is also dependent on residues an structure are the protein of or the protein of W.J. J. Virol. 2002; 83: PubMed Scopus Google Scholar, S. Virology. 1998; PubMed Scopus Google Scholar). these proteins the residues essential for oligomerization are the The three leucines that are for VP30 oligomerization are to other and different the It is that the leucines are essential to support the of the that in is for VP30 The that the leucine cluster is highly in VP30 of the virus further to an role of this experiments that virus VP30 is also present as an not When the VP30 mutants were for their to with NP inclusions that of nucleocapsid-like structures, was found that oligomerization was not for binding to the NP This suggested that the domain of VP30 is not by the oligomerization of the protein. A similar has been for the protein of virus of the complex P protein and the nucleocapsid protein N and interaction with the N RNA template were of P protein oligomerization B.P. Virology. 2002; PubMed Scopus Google Scholar). In a minigenome VP30 has been to viral transcription efficiently (7Mühlberger E. Weik M. Volchkov V.E. Klenk H.-D. Becker S. J. Virol. 1999; 73: 2333-2342Crossref PubMed Google Scholar). When VP30 mutants were used in the EBOV-specific that the transcription activation function of the protein was This suggested that the of VP30 is a complex of VP30 This was by the finding that inactive VP30 mutants a dominant negative effect on transcription. In contrast, inactive and oligomerization-deficient VP30 mutants not the of VP30. It is that viral and transcription factors are functional as Thus, the virus protein represents a of viral and genes and as a PubMed Scopus Google Scholar). The of the gene is and the oligomerization is by a domain whose integrity is essential for DNA binding 2001; PubMed Scopus Google Scholar). many other or proteins like the protein and the of virus or the are as oligomers M. H. G. M. J. J. Virol. 1998; PubMed Google Scholar, J. Virol. 1998; PubMed Google Scholar, V.A. J. Virol. 2001; PubMed Scopus Google Scholar). is not yet whether VP30 binds RNA VP30 is essential for a very early of transcription that is by an RNA secondary structure that was found to be present in the EBOV genome and in the of the first gene VP30 as a that the polymerase complex to overcome the secondary This be from the finding of the secondary EBOV transcription of VP30 (10Weik M. Modrof J. Klenk H.D. Becker S. Mühlberger E. J. Virol. 2002; 76: 8532-8539Crossref PubMed Scopus (120) Google Scholar). of the VP30 amino sequence revealed a at amino acids that is for the of RNA Biol. 2002; PubMed Scopus Google Scholar). The in this has been to with RNA Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar). VP30 as a to be VP30 oligomerization could be inhibited by a peptide consisting of amino acids that were to the presumed oligomerization domain of VP30 the leucine In contrast, oligomerization was not inhibited by a peptide in which three of the four leucines were by of protein oligomerization with is a used For et al. S. H. L. H. H. S. 2001; PubMed Scopus Google Scholar) used to the of the virus and and S. 2002; PubMed Scopus Google Scholar) inhibition of the of and by In the sequence of the used was derived from interaction of the respective protein While the for inhibition of the of was the by of virus into the genome was The of for the inhibition of VP30 oligomerization by E30pep-wt that the peptide efficiently the VP30 To the role of VP30 oligomerization in the of the viral EBOV-infected cells were transfected with The resulting inhibition of EBOV was the control peptide not a inhibitory effect. These that oligomerization of VP30 is essential for EBOV propagation. the function of homo-oligomerization have been for the protein of virus which is a viral J. Virol. 1998; PubMed Google Scholar). of and inactive forms of a mixed is formed resulting in an inactive The of E30pep-wt that was to the EBOV infection was the used in the in one this is to the to the peptide into the the other E30pep-wt had to with the VP30 that is into the cell by the In the that VP30 oligomerization is dependent on a cluster of amino acids with four central leucine Mutation of the leucine residues the EBOV transcription. EBOV propagation was impaired upon inhibition of VP30 oligomerization by that were to the presumed oligomerization
31
Thomas R. Fuerst, Edward G. Niles, F. William Studier et al. · Proceedings of the National Academy of Sciences · 1986 · 2.1K citations · Full text
Ursula J. Buchholz, Stefan Finke, Karl‐Klaus Conzelmann · Journal of Virology · 1999 · 1.1K citations · Full text